GAITHERSBURG, Md., Nov. 3 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, November 9, 2020.
Conference call details are as follows:
|Date:||November 9, 2020|
|Time:||4:30 p.m. U.S. Eastern Time (ET)|
|Dial-in number:||(877) 212-6076 (Domestic) or (707) 287-9331 (International)|
|Webcast:||www.novavax.com, “For Investors”/ “Events”|
Conference call and webcast replay:
|Dates:||Starting at 7:30 p.m. ET, November 9, 2020 until|
|7:30 p.m. ET November 16, 2020|
|Dial-in number:||(855) 859-2056 (Domestic) or (404) 537-3406 (International)|
|Webcast:||www.novavax.com, “For Investors”/ “Events”, until February 9, 2021|
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is currently conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the virus that causes COVID-19, including a pivotal Phase 3 clinical trial in the United Kingdom to evaluate the efficacy, safety and immunogenicity in individuals aged 18-84 years of age. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both candidate vaccines incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
Source: Novavax, Inc. via GLOBE NEWSWIRE